G. O’Riordan

Safety and feasibility of oral immunotherapy to multiple allergens for food allergy

Anthony Trela, S. Seki, K. Nadeau, 2014, Allergy, Asthma & Clinical Immunology.

Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab

Anthony Trela, S. Seki, K. Nadeau, 2014, Allergy, Asthma & Clinical Immunology.

Erratum to: Safety and feasibility of oral immunotherapy to multiple allergens for food allergy

Anthony Trela, K. Nadeau, A. Mehrotra, 2016, Allergy, Asthma & Clinical Immunology.

Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3).

Stephen J Galli, Holden Maecker, Kari C Nadeau, 2014, The Journal of allergy and clinical immunology.

Research Participant‐Centered Outcomes at NIH‐Supported Clinical Research Centers

Sylvia Baedorf Kassis, Mary T. Roth, B. Coller, 2014, Clinical and translational science.

Research Participant‐Centered Outcomes at NIH‐Supported Clinical Research Centers

Sylvia Baedorf Kassis, Mary T. Roth, B. Coller, 2014, Clinical and translational science.

Low-fluoroscopy atrial fibrillation ablation with contact force and ultrasound technologies: a learning curve

Paul C. Zei, T. Baykaner, C. Brodt, 2019, Pragmatic and observational research.

Erratum to: Safety and feasibility of oral immunotherapy to multiple allergens for food allergy

K. Nadeau, A. Mehrotra, R. Hamilton, 2016, Allergy, Asthma & Clinical Immunology.

Recommendations From the Investigational New Drug/Investigational Device Exemption Task Force of the Clinical and Translational Science Award Consortium

Joan E. Adamo, Karen A. Hartman, K. Schuff, 2014, Journal of Investigative Medicine.